FDA clears Anavex IND for blarcamesine Phase 2a trial in Fragile X syndrome
Anavex Life Sciences received FDA clearance to proceed with its Investigational New Drug application for blarcamesine (ANAVEX®2‑73) in Fragile X syndrome. The company will launch a randomized, double‑blind, placebo‑controlled Phase 2a study of approximately 60 adult male participants to assess safety, tolerability and pharmacokinetics. The clearance adds Fragile X to the three core indications—Alzheimer’s disease, Rett syndrome and Fragile X—where Anavex now holds open INDs. Blarcamesine also retains its FDA Orphan Drug designation for this rare disorder.
Why it matters
The FDA IND clearance removes a regulatory barrier, allowing Anavex to begin human testing in Fragile X and potentially expand the commercial scope of its lead investigational therapy. The announcement may improve investor confidence in the company’s ability to advance its pipeline, though commercial impact will depend on future trial results.
Key facts
- 1The U.S. FDA cleared Anavex’s IND for blarcamesine in Fragile X syndrome, enabling the planned clinical study. stocktitan.net
- 2Anavex plans a Phase 2a randomized, double‑blind, placebo‑controlled, dose‑ranging study of blarcamesine oral solution in approximately 60 adult males with Fragile X syndrome. rttnews.com
- 3Blarcamesine has previously received FDA Orphan Drug Designation for Fragile X syndrome. rttnews.com
- 4The IND clearance gives Anavex open INDs in three core indications: Alzheimer’s disease, Rett syndrome and Fragile X syndrome. stocktitan.net
- 5AVXL’s stock closed at $1.48, down 0.67%, on the day of the announcement. rttnews.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.